An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.

Also called NCT07234032

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 344 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07234032
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Czechia, France, Georgia, Germany, Japan, South Korea, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07234032. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2031-01-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Condition
Interstitial Lung Disease
Intervention (Drug)
Treprostinil Palmitil Inhalation Powder
Intervention (Drug)
Placebo
Lead sponsor
Insmed Incorporated (class: industry)

Record details

Record id
cardio:ct-nct07234032
Content hash
589fba4f0cf6a75448f6249e95a2a0b124b545dcbab7b8dcb2c4725f2e4f3cd6